Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.

ABSTRACT:

Background

Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs.

Methods

In-depth multi-omics analyses included whole exome and transcriptome sequencing to define individual patient-specific search spaces of neoepitope candidates. Evidence for the natural presentation of mutated HLA ligands was investigated through an in silico pipeline integrating proteome and HLA ligandome profiling data.

Results

The approach was successfully validated in a state-of-the-art dataset from malignant

SUBMITTER: Loffler MW 

PROVIDER: S-EPMC6492406 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature